Open AccessNivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer
Author(s) -
Jane E. Rogers,
Lianchun Xiao,
Allison Trail,
Mariela Blum Murphy,
Melissa Palmer,
Jaffer A. Ajani
Publication year - 2020
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000505974
Subject(s) - irinotecan , medicine , nivolumab , folfiri , ramucirumab , oncology , capecitabine , refractory (planetary science) , gastroenterology , cancer , progression free survival , taxane , performance status , surgery , chemotherapy , colorectal cancer , breast cancer , immunotherapy , physics , astrobiology
Advanced unresectable gastroesophageal cancers continue to confer a dismal patient prognosis. Limited options remain once the cancer is refractory to cytotoxics/biologics (like irinotecan, taxane, and ramucirumab). Recently, anti-programmed death-1 (anti-PD-1) inhibitors have been used with limited efficacy in select patients with adenocarcinoma. Similarly, irinotecan-based therapy has marginal efficacy. We combined irinotecan plus a fluoropyrimidine with an anti-PD-1 antibody, nivolumab, with hopes of having a higher advantage for patients.